Summary

  • IPEX and GOWell removed post-closing lockups from 3,337,500 shares expected to be held by two sponsors and two capital-markets representatives. The change takes effect at closing; it does not show that any share was sold.
  • A separate 4,481,250-share grant for specified officers and directors may vest 90 days after closing, subject to continued service, and then carries no further lockup.
  • Investors had already redeemed 7,475,610 of the SPAC’s 8,625,000 original public shares. The two disclosed share groups are therefore large beside the 1,149,390-share public residue, but that residue is not the future float denominator.

The last amendment before Inflection Point Acquisition Corp. V’s scheduled 3 September shareholder meeting did not inject cash into the proposed GOWell transaction. It changed time.

The 31 August Form 8-K says IPEX and GOWell ended every specified post-closing transfer restriction applying to Inflection Point Fund I, LP, Maywood Sponsor, LLC, Cohen & Company Capital Markets and Seaport Global Securities. The filing gives the outcome directly: after closing, 3,337,500 GOWell Energy Technology ordinary shares collectively held by those parties will be freely tradeable and not subject to lockup restrictions.

That sentence creates a permission. It is not a transaction report. No holder is said to have placed an order, registered a particular disposal or committed to sell. Closing itself has not occurred in the frozen record. The useful market question is therefore not “how many shares were dumped?” It is “which contractual barrier disappears, for whose shares, and at what event?”

Three agreement changes reach the same closing gate

The mechanism sits in three documents. The third amendment to the Business Combination Agreement deletes the sponsor lockup form and narrows the remaining closing lockup covenant to holders of GOWell ordinary shares immediately before the second merger becomes effective. The SPAC Holders Support Agreement amendment leaves a new registration-rights agreement as the relevant closing deliverable, without the sponsor lockup deliverable. The omnibus insider and underwriting amendment terminates the insider, private-placement and underwriting lockups when the business combination closes.

The amendments do not make closing automatic. They make closing the switch. If shareholder approval or another condition fails, the stated release does not reach its effective state.

The change also does not erase every legal boundary around a future sale. The supplement describes the relevant shares as freely tradeable and not subject to these lockups. Securities-law limits can still turn on whether a seller is a PubCo affiliate and whether the disposition satisfies an available registration or resale route. “No contractual lockup” should not be expanded into “no legal conditions.”

Redemptions changed the scale of the comparison

IPEX raised US$86.25 million in February 2025 by selling 8,625,000 public units at US$10. Each unit contained one Class A share and a right to receive one-fifth of a share if an initial business combination completes.

The capital base then contracted. At the August extension vote, holders redeemed 7,475,610 public shares for about US$79.1 million, or roughly US$10.59 each. The extension-vote Form 8-K says approximately US$12,166,471 remained in trust. The later quarterly report repeats the redemption and trust-account boundary.

Simple subtraction leaves 1,149,390 of the original public shares unredeemed: 13.3% remained and 86.7% was redeemed. Against that known comparator, the 3,337,500-share closing release is about 2.90 times as large.

But 1,149,390 is not a forecast of post-combination float. After the redemptions, IPEX reported 4,433,765 ordinary shares outstanding, including 3,443,765 Class A and 990,000 Class B shares. The eventual PubCo denominator will also include transaction shares, the conversion of public rights, GOWell holders, restricted shares and any applicable financing instruments. A clean comparison can show relative scale without pretending to calculate dilution or tradable supply.

Day 90 is a different contract

The proxy statement/prospectus supplement identifies a second group. Before the second merger becomes effective, GOWell is to issue 4,481,250 Company Restricted Shares to specified SPAC officers and directors for services rendered and to be rendered. Those shares convert one-for-one into PubCo Restricted Shares. They vest 90 days after closing, subject to continued service, and carry no further lockup.

The expected allocation is concentrated: 3,315,938 shares to IPEX chairman and chief executive Michael Blitzer; 1,105,312 to chief operating officer Kevin Shannon; and 20,000 each to directors William Denkin, Steven Tannenbaum and Carolyn Trabuco. The supplement illustrates an aggregate value of about US$47.37 million using IPEX’s US$10.57 closing price on 10 August, while also warning that vesting makes the shares less valuable. That is a historical illustration, not current proceeds or a valuation of GOWell.

This second clock cannot be added mechanically to the first. The 3,337,500 shares lose specified contractual restraints at closing. The 4,481,250 restricted shares must first be issued and converted, then satisfy continued service through day 90 before vesting. One is a release from a restraint; the other is an acquisition of an unconditional right.

Together the groups total 7,818,750 shares, about 6.80 times the unredeemed-public-share comparator. That ratio is useful only as a prompt for denominator work. It is not a prediction that 7,818,750 shares will enter the market, trade on one day or depress the price.

The filed deadline cannot be silently repaired

The supplement schedules the extraordinary meeting for 3 September 2026. Under a heading “New Redemption Deadline,” however, it says every proxy reference is amended to 5:00 p.m. Eastern Time on 2 September 2025. The supplement and 8-K are dated 31 August 2026.

The year is internally inconsistent with the surrounding timetable. The public record does not authorize an editor to convert it to 2026. The disciplined treatment is to preserve the filed year, identify the conflict and ask for authoritative confirmation from the company or transfer agent. A date that governs an exit right is a control field, not a typo to normalize in private.

The meeting result is now the first missing receipt. Approval would still not prove closing. Closing would activate the first share-permission clock. Continued service through the 90th day would determine the second. Actual sales, if any, would require their own evidence. Keeping those events separate is how investors avoid turning a change in contractual optionality into a claim about completed market supply.

Sources